Stockreport

Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)

Dicerna Pharmaceuticals, Inc.  (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com
PDF – Study Met Primary Safety Endpoint; Nedosiran Shown to be Generally Safe and Well Tolerated in Patients With PH3 –– Although Trial Did Not Meet Prespecified Secondary E [Read more]